Skip to Content

Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Does Not Change OS

The results of the Scandinavian NeoCol trial, presented at ASCO23, indicate that there is no significant difference in DFS and OS between neoadjuvant chemotherapy (CapOX regimen – oxaliplatin plus capecitabine) in patients with locally advanced colon cancer compared to standard upfront surgery. Let’s hear more from Lars Henrik Jensen as he elaborates on these findings.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top